Guiyu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guiyu Wang has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Chunlin Wang
Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China
9 shared publicationsWeiyuan Zhang
Department of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, China
8 shared publicationsHao Zhang
Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China
7 shared publicationsZiming Yuan
Department of Colorectal Surgery The Second Affiliated Hospital of Harbin Medical University Harbin China
7 shared publicationsHanqing Hu
Department of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, China
6 shared publicationsJun Xiang
Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China
6 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
Peritumoral Malignant Cellular Foci Performs Better Than Tumor Budding and Poorly Differentiated Cluster in Risk Stratification of Lymph Node Metastasis in pT1 Colorectal Cancer
As biomarkers separated by the arbitrary 5-tumor-cell cutoff at the tumor invasive front, tumor budding (TB) and poorly differentiated clusters (PDC) are recognized as high-risk factors for lymph node metastasis (LNM) in pT1 colorectal cancer (CRC). Nonetheless, relevant findings remain inconsistent. Furthermore, the association between the tumor invasive front biomarker and D3 LNM in pT1 CRC remains unknown. To identify a biomarker that captures the full morphologic spectrum and eliminates the need for such cutoffs at the tumor invasive front for predicting LNM, particularly D3 LNM, in pT1 CRC, we defined peritumoral malignant cellular foci (PMCF) as nonglandular foci composed of ≥1 tumor cell at the tumor invasive front. After enrolling 2611 endoscopically or surgically resected pT1 CRC patients from 6 high-volume Chinese institutions, we found that neither TB nor PDC exhibited a consistent independent association with LNM across the training and validation cohorts. In contrast, PMCF emerged as an independent risk factor with superior risk stratification of LNM in both cohorts ( P P P <0.05). In conclusion, PMCF not only suggests additional radical surgery after endoscopic resection in pT1 CRC, but may also indicate D3 lymph node dissection. PMCF provides an evidence-based rationale to optimize surgical decision-making in pT1 CRC.
- 14 October 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
Open AccessPeritumoral Malignant Cellular Foci Performs Better Than Tumor Budding and Poorly Differentiated Cluster in Risk Stratification of Lymph Node Metastasis in pT1 Colorectal Cancer
As biomarkers separated by the arbitrary 5-tumor-cell cutoff at the tumor invasive front, tumor budding (TB) and poorly differentiated clusters (PDC) are recognized as high-risk factors for lymph node metastasis (LNM) in pT1 colorectal cancer (CRC). Nonetheless, relevant findings remain inconsistent. Furthermore, the association between the tumor invasive front biomarker and D3 LNM in pT1 CRC remains unknown. To identify a biomarker that captures the full morphologic spectrum and eliminates the need for such cutoffs at the tumor invasive front for predicting LNM, particularly D3 LNM, in pT1 CRC, we defined peritumoral malignant cellular foci (PMCF) as nonglandular foci composed of ≥1 tumor cell at the tumor invasive front. After enrolling 2611 endoscopically or surgically resected pT1 CRC patients from 6 high-volume Chinese institutions, we found that neither TB nor PDC exhibited a consistent independent association with LNM across the training and validation cohorts. In contrast, PMCF emerged as an independent risk factor with superior risk stratification of LNM in both cohorts ( P P P <0.05). In conclusion, PMCF not only suggests additional radical surgery after endoscopic resection in pT1 CRC, but may also indicate D3 lymph node dissection. PMCF provides an evidence-based rationale to optimize surgical decision-making in pT1 CRC.
- Open Access
- 17 August 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1884577
Synchronous multiple primary colorectal cancer with discordant RAS status between primary lesions: a case report in an elderly patient
Background: Synchronous multiple primary colorectal cancer (SMPCRC) is rare and often shows molecular heterogeneity between primary lesions. Treatment decisions are particularly challenging in complex scenarios involving multiple independent lesions, distant metastasis, and advanced age with intolerance to standard chemotherapy. Case presentation: A 77-year-old man presented with hematochezia and was diagnosed with four independent neoplastic lesions within three months: a primary rectal lesion (pT3N1aM0), a sigmoid colon primary carcinoma, a proximal rectal adenoma with focal intramucosal carcinoma, and an adenocarcinoma of the transverse colon near the splenic flexure [resected by endoscopic submucosal dissection (ESD) three months later]. Bilateral hepatic metastases were detected six months postoperatively, with the carcinoembryonic antigen (CEA) level still within the reference range at diagnosis. Molecular testing of the two primary carcinomas revealed marked discordance: the primary rectal lesion carried mutation signals in both KRAS exon 4 and NRAS exon 2, whereas the sigmoid colon lesion was entirely RAS/RAF/PIK3CA wild-type — testing either lesion alone would have led to opposite anti-EGFR treatment decisions. Given the patient's advanced age and intolerance to standard chemotherapy, a staged, multimodal integrated strategy was adopted: synchronous surgery for three primary lesions, minimally invasive ESD of the transverse colon lesion, artificial ascites-assisted percutaneous microwave ablation (AA-MWA) for liver metastases, and individualized adjustment of chemotherapy (switched from CAPEOX to oxaliplatin plus raltitrexed because of intolerance). Over 18 months of follow-up, no radiological recurrence was observed and the patient remained in good general condition. Conclusions: This case demonstrates that primary lesions in SMPCRC can harbor substantial molecular heterogeneity, such that single-lesion testing may be insufficient to guide treatment decisions in complex scenarios. For elderly patients intolerant to standard regimens, a staged, multimodal integrated approach (synchronous surgery + ESD + AA-MWA + individualized chemotherapy adjustment) may serve as a feasible comprehensive treatment option.
- 17 August 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1884577
Open AccessSynchronous multiple primary colorectal cancer with discordant RAS status between primary lesions: a case report in an elderly patient
Background: Synchronous multiple primary colorectal cancer (SMPCRC) is rare and often shows molecular heterogeneity between primary lesions. Treatment decisions are particularly challenging in complex scenarios involving multiple independent lesions, distant metastasis, and advanced age with intolerance to standard chemotherapy. Case presentation: A 77-year-old man presented with hematochezia and was diagnosed with four independent neoplastic lesions within three months: a primary rectal lesion (pT3N1aM0), a sigmoid colon primary carcinoma, a proximal rectal adenoma with focal intramucosal carcinoma, and an adenocarcinoma of the transverse colon near the splenic flexure [resected by endoscopic submucosal dissection (ESD) three months later]. Bilateral hepatic metastases were detected six months postoperatively, with the carcinoembryonic antigen (CEA) level still within the reference range at diagnosis. Molecular testing of the two primary carcinomas revealed marked discordance: the primary rectal lesion carried mutation signals in both KRAS exon 4 and NRAS exon 2, whereas the sigmoid colon lesion was entirely RAS/RAF/PIK3CA wild-type — testing either lesion alone would have led to opposite anti-EGFR treatment decisions. Given the patient's advanced age and intolerance to standard chemotherapy, a staged, multimodal integrated strategy was adopted: synchronous surgery for three primary lesions, minimally invasive ESD of the transverse colon lesion, artificial ascites-assisted percutaneous microwave ablation (AA-MWA) for liver metastases, and individualized adjustment of chemotherapy (switched from CAPEOX to oxaliplatin plus raltitrexed because of intolerance). Over 18 months of follow-up, no radiological recurrence was observed and the patient remained in good general condition. Conclusions: This case demonstrates that primary lesions in SMPCRC can harbor substantial molecular heterogeneity, such that single-lesion testing may be insufficient to guide treatment decisions in complex scenarios. For elderly patients intolerant to standard regimens, a staged, multimodal integrated approach (synchronous surgery + ESD + AA-MWA + individualized chemotherapy adjustment) may serve as a feasible comprehensive treatment option.
- Open Access
- 31 July 2026
- Published by Elsevier in Translational Oncology
- Vol. 72, 102948
A Multi-omics Regulated Cell Death Framework Defines Immune Phenotypes and Guides Precision Therapy in Colorectal Cancer
- 31 July 2026
- Published by Elsevier in Translational Oncology
- Vol. 72, 102948
Open AccessA Multi-omics Regulated Cell Death Framework Defines Immune Phenotypes and Guides Precision Therapy in Colorectal Cancer
- 25 July 2026
- Published by Elsevier in Cellular Signalling
- Vol. 147, 112766
PTPN14 functions as an oncogenic promoter in colon adenocarcinoma and liver hepatocellular carcinoma via Notch Signaling
- 25 July 2026
- Published by Elsevier in Cellular Signalling
- Vol. 147, 112766
PTPN14 functions as an oncogenic promoter in colon adenocarcinoma and liver hepatocellular carcinoma via Notch Signaling
- Open Access
- 25 June 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Deep learning-driven MRI radiomics reveals biological subtypes and predicts recurrence risk in rectal cancer
Traditional TNM staging inadequately captures the recurrence risk of rectal cancer (RC), limiting prognostic accuracy and personalized treatment decisions. Here, we developed an MRI-based deep learning approach to predict recurrence risk and leveraged pathology and transcriptomic analyses to characterize tumor heterogeneity and provide biological interpretation. In this multicenter study of 2060 patients without neoadjuvant therapy across four independent cohorts (training: n = 931; internal validation: n = 365; external validation: n = 492; biological: n = 272), unsupervised clustering of deep learning-extracted radiomic features identified three biologically distinct radiomics-based deep learning subtypes (RDLSs). Comprehensive molecular profiling using single-cell RNA sequencing (n = 7), bulk RNA sequencing (n = 83), and whole-slide imaging (n = 409) revealed that RDLS1 exhibited an immune-excluded phenotype with poor prognosis, RDLS2 showed enriched lymphocyte infiltration with favorable outcomes, and RDLS3 displayed intermediate prognosis with abundant stromal elements. Multivariate Cox analysis confirmed independent prognostic value across all cohorts (RDLS2 vs. RDLS1: HR = 0.52, 95% CI: 0.29-0.82, p = 0.003). Leveraging high-risk RDLS1 features, we developed a recurrence risk scoring system (RRS) that effectively stratified patients across cohorts. Compared with the clinical model alone, integration of the RRS with clinical variables improved 5-year RFS prediction performance, increasing the AUC from 0.799 to 0.834 in the training cohort and from 0.780 to 0.825 in the external validation cohort. This noninvasive and biologically interpretable framework bridges imaging phenotypes to molecular characteristics, providing a potential approach for recurrence risk assessment and more individualized postoperative risk stratification in RC patients without neoadjuvant therapy.
- 25 June 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessDeep learning-driven MRI radiomics reveals biological subtypes and predicts recurrence risk in rectal cancer
Traditional TNM staging inadequately captures the recurrence risk of rectal cancer (RC), limiting prognostic accuracy and personalized treatment decisions. Here, we developed an MRI-based deep learning approach to predict recurrence risk and leveraged pathology and transcriptomic analyses to characterize tumor heterogeneity and provide biological interpretation. In this multicenter study of 2060 patients without neoadjuvant therapy across four independent cohorts (training: n = 931; internal validation: n = 365; external validation: n = 492; biological: n = 272), unsupervised clustering of deep learning-extracted radiomic features identified three biologically distinct radiomics-based deep learning subtypes (RDLSs). Comprehensive molecular profiling using single-cell RNA sequencing (n = 7), bulk RNA sequencing (n = 83), and whole-slide imaging (n = 409) revealed that RDLS1 exhibited an immune-excluded phenotype with poor prognosis, RDLS2 showed enriched lymphocyte infiltration with favorable outcomes, and RDLS3 displayed intermediate prognosis with abundant stromal elements. Multivariate Cox analysis confirmed independent prognostic value across all cohorts (RDLS2 vs. RDLS1: HR = 0.52, 95% CI: 0.29-0.82, p = 0.003). Leveraging high-risk RDLS1 features, we developed a recurrence risk scoring system (RRS) that effectively stratified patients across cohorts. Compared with the clinical model alone, integration of the RRS with clinical variables improved 5-year RFS prediction performance, increasing the AUC from 0.799 to 0.834 in the training cohort and from 0.780 to 0.825 in the external validation cohort. This noninvasive and biologically interpretable framework bridges imaging phenotypes to molecular characteristics, providing a potential approach for recurrence risk assessment and more individualized postoperative risk stratification in RC patients without neoadjuvant therapy.
- 1 June 2026
- Published by Wiley in Colorectal Disease
- Vol. 28 (6) , e70514
Laparoscopic right hemicolectomy with D3 lymph node dissection and Transanal specimen extraction ( NOSES VIIIB ) in a young woman: A video vignette
- 1 June 2026
- Published by Wiley in Colorectal Disease
- Vol. 28 (6) , e70514
Laparoscopic right hemicolectomy with D3 lymph node dissection and Transanal specimen extraction ( NOSES VIIIB ) in a young woman: A video vignette
- Open Access
- 16 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (6) , 12679-12686
Prospective single-arm study of gastric surgery in experimental animals assisted by Kangduo surgical robot
Objective: To investigate the feasibility, efficacy, and safety of gastric surgery in experimental animals assisted by the domestic Kangduo Surgical Robot 2000 (SR2000). Methods: Eight porcine models were prospectively enrolled between August and December 2023 at Harbin SAGEBOT Intelligent Medical Animal Experiment Center. Preoperative baseline characteristics, intraoperative physiological parameters, surgical procedure, and postoperative assessments and investigations were recorded to compare the feasibility, efficacy, and safety evaluation indexes of experimental animals in the perioperative period. The primary endpoint was surgical success rate. The secondary endpoints were operative workflow parameters, intraoperative blood loss, postoperative laboratory changes, perioperative adverse events, and surgeon workload assessed using the NASA-TLX instrument. Results: In eight experimental pig models, the SR2000 successfully assisted in the completion of partial gastrectomy. All surgeries were completed according to plan, with no intermediate open or intraoperative complications, and the perioperative survival rate of animals was 100%. The mean operation time of partial gastrectomy was 76.75 min (range: 50–105 min), and the positioning time was 6–17 min. Intraoperative bleeding was ≤5 ml in all the animals, and some animals showed elevated white blood cell counts and neutrophil counts (Neu) on the first day of the postoperative period. The liver and kidney function indexes (alanine aminotransferase, blood urea nitrogen, creatinine) were not significantly abnormal before and after surgery. The anastomosis healed well without complications such as infection and anastomotic fistula. Conclusion: The feasibility, efficacy, and safety of the SR2000 were verified in animal experiments, and ergonomically optimized design have the potential for clinical dissemination.
- 16 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (6) , 12679-12686
Open AccessProspective single-arm study of gastric surgery in experimental animals assisted by Kangduo surgical robot
Objective: To investigate the feasibility, efficacy, and safety of gastric surgery in experimental animals assisted by the domestic Kangduo Surgical Robot 2000 (SR2000). Methods: Eight porcine models were prospectively enrolled between August and December 2023 at Harbin SAGEBOT Intelligent Medical Animal Experiment Center. Preoperative baseline characteristics, intraoperative physiological parameters, surgical procedure, and postoperative assessments and investigations were recorded to compare the feasibility, efficacy, and safety evaluation indexes of experimental animals in the perioperative period. The primary endpoint was surgical success rate. The secondary endpoints were operative workflow parameters, intraoperative blood loss, postoperative laboratory changes, perioperative adverse events, and surgeon workload assessed using the NASA-TLX instrument. Results: In eight experimental pig models, the SR2000 successfully assisted in the completion of partial gastrectomy. All surgeries were completed according to plan, with no intermediate open or intraoperative complications, and the perioperative survival rate of animals was 100%. The mean operation time of partial gastrectomy was 76.75 min (range: 50–105 min), and the positioning time was 6–17 min. Intraoperative bleeding was ≤5 ml in all the animals, and some animals showed elevated white blood cell counts and neutrophil counts (Neu) on the first day of the postoperative period. The liver and kidney function indexes (alanine aminotransferase, blood urea nitrogen, creatinine) were not significantly abnormal before and after surgery. The anastomosis healed well without complications such as infection and anastomotic fistula. Conclusion: The feasibility, efficacy, and safety of the SR2000 were verified in animal experiments, and ergonomically optimized design have the potential for clinical dissemination.
- Open Access
- 7 March 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
OSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity
Colorectal cancer progression involves dysregulated signaling pathways such as Hippo-YAP, but upstream regulators remain poorly defined. Here we demonstrate that oxysterol-binding protein-like 3 (OSBPL3) modulates Hippo-YAP signaling to drive tumor aggressiveness. Analysis of clinical specimens and experimental models shows that elevated OSBPL3 levels in colorectal cancer tissues correlate with shortened patient survival. Depleting OSBPL3 impairs cancer cell proliferation and invasion and induces cell cycle arrest, while its overexpression accelerates tumor growth. Mechanistic studies reveal that OSBPL3 binds 14-3-3 proteins to promote YAP1 nuclear translocation, activating downstream oncogenic pathways. Notably, tumors with high OSBPL3 expression exhibit resistance to MEK inhibitors, but this resistance is overcome by YAP1 suppression or combined YAP/MEK inhibition in patient-derived organoids. These results establish OSBPL3 as a critical Hippo-YAP pathway regulator and propose targeting OSBPL3-mediated signaling as a therapeutic strategy for colorectal cancers with Hippo pathway alterations.
- 7 March 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessOSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity
Colorectal cancer progression involves dysregulated signaling pathways such as Hippo-YAP, but upstream regulators remain poorly defined. Here we demonstrate that oxysterol-binding protein-like 3 (OSBPL3) modulates Hippo-YAP signaling to drive tumor aggressiveness. Analysis of clinical specimens and experimental models shows that elevated OSBPL3 levels in colorectal cancer tissues correlate with shortened patient survival. Depleting OSBPL3 impairs cancer cell proliferation and invasion and induces cell cycle arrest, while its overexpression accelerates tumor growth. Mechanistic studies reveal that OSBPL3 binds 14-3-3 proteins to promote YAP1 nuclear translocation, activating downstream oncogenic pathways. Notably, tumors with high OSBPL3 expression exhibit resistance to MEK inhibitors, but this resistance is overcome by YAP1 suppression or combined YAP/MEK inhibition in patient-derived organoids. These results establish OSBPL3 as a critical Hippo-YAP pathway regulator and propose targeting OSBPL3-mediated signaling as a therapeutic strategy for colorectal cancers with Hippo pathway alterations.
- 18 February 2026
- Published by Elsevier in Experimental Cell Research
- Vol. 457 (2) , 114944
DSN1 promotes colorectal cancer metastasis by Inhibiting FZR1-Mediated ubiquitination of c-MYC
- 18 February 2026
- Published by Elsevier in Experimental Cell Research
- Vol. 457 (2) , 114944
DSN1 promotes colorectal cancer metastasis by Inhibiting FZR1-Mediated ubiquitination of c-MYC
- Open Access
- 26 December 2025
- Published by Elsevier in Cell Reports
- Vol. 45 (1) , 116774
Lactylation-stabilized NOL6 promotes colorectal cancer progression via STAMBP-mediated YY1 deubiquitination and c-Myc transcription upregulation
- 26 December 2025
- Published by Elsevier in Cell Reports
- Vol. 45 (1) , 116774
Open AccessLactylation-stabilized NOL6 promotes colorectal cancer progression via STAMBP-mediated YY1 deubiquitination and c-Myc transcription upregulation